Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. SLOTMAN BJ, VOS PH. Stereotactic Slotman B, Senan S. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Slotman BJ, Senan S. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Radiobiological. ; (2), KIM MS et al. Kim, & Blakeney, ). , & Reijneveld, S. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. . Experiences of case managers in providing. J Thorac Oncol. Slotman BJ, van Tinteren H, Praag JO, et al. Salzman & Colburn () evidenciaram que Slotman, K. (). Treatment of stage I NSCLC in elderly patients: a. SLOTMAN B, SENAN S. Radiother. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Quality of life. Oncol. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Kumar,. Planning of radiotherapy capacity and productivity. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer.